ETMOZYN (Aetmozinum; synonym: Ethmozin, Moracizin hydrochlorid; joint venture. B) — antiarrhythmic means. 2-Karbetoksiamino-10-(3-mor-
folinopropionit) - a fenotiazina a hydrochloride; C22H25N 304S • HC1:
Crystal powder, white or white with a cream shade. Let's dissolve in water, it is badly alcohol-soluble; pier. weight (weight) 463,97. Water solutions for injections (pH of 2,5% of solution 3,5 — 4,2) are prepared, filtering via the sterilizing filter.
On pharmakol. to properties and the mechanism of action it is close to quinidine (see). Antiarrhythmic effect E. it is caused by its ability to oppress in cells of a myocardium the bystry entering sodium current. AA. stops the arrhythmias caused by increase in automatism due to reduction of the maximum speed of depolarization of action potential that is followed by reduction of speed of carrying out an impulse with simultaneous increase in an excitation threshold and duration of the effective refractory period. Unlike other drugs of this group E. does not cause decrease in the ABP, does not exert impact on contractility of a myocardium, atrioventricular and intra ventricular conductivity. It is well soaked up in blood at any ways of introduction. Period of semi-life E. at single introduction inside makes
3 — 5 hour. The maximum level in a blood plasma at course use inside remains within
2 — 6 days. Efficiency concentration in plasma of 0,8 mkg! ml. Drug is considerably metabolized in a liver. AA. and products of his metabolism are removed with urine and a stake.
Apply to treatment of supraventricular and ventricular arrhythmias of various etiology: premature ventricular contraction, Bouveret's disease, paroxysms of a ciliary tachyarrhythmia. The most important aspect of practical application E. treatment of ventricular forms of arrhythmias at patients with coronary heart disease is.
Appoint inside, intramusculary and intravenously. Doses of drug can be varied widely. Inside the adult in an initiation of treatment appoint 100 — 200 mg a day. In the absence of effect the daily dose is increased to 300 — 600 mg. Maintenance doses make 2/3 from maximum. Intramusculary appoint on 2 — 6 ml 2,5% of solution of an Ethmosinum with 1 — 2 ml of 0,25 — 0,5% of solution of novocaine. Intravenously enter
2 — 6 ml of 2,5% of solution of the drug divorced in 10 ml of isotonic solution of sodium of chloride or 5% of solution of glucose. Injections make slowly (within 5 — 7 min.).
Drug is usually well transferred. In some cases at reception E. inside there can be nausea, edges stops at reduction of a dose of drug. At intravenous administration perhaps slight dizziness, for the prevention to-rogo it is necessary to watch rate of administering of drug.
AA. it is contraindicated at hron. diseases of a liver and kidneys.
Form of release: tablets on
0,025 and 0,1 g; ampoules on 2 ml of 2,5% of solution. Storage: in the dry, cool, protected from light place.
See also Antiarrhythmic means.
Bibliogrvnezapny death, under the editorship of
A. M. Vikherta and B. Launa, M., 1980;
Kaverina N. V., etc. About antiarrhythmic properties of an Ethmosinum, Pharm. and toksikol., t. 33, JSTs 6, page 693, 1970; Clinical pharmacology, under the editorship of
B. V. Zakusova, M., 1978; Blizzards
tsa V. I. Reference book of the cardiologist on clinical pharmacology, M., 1980.
N. V. Kaverina.